Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229154 | 0.87 | ESR1 (0.47) | S1PR1HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL2228824 | 0.87 | S1PR1 (0.42) | S1PR1NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2223582 | 0.85 | S1PR1 (0.47) | S1PR1 | |
| SCHEMBL2228838 | 0.82 | HPGD (0.47) | S1PR1NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2225593 | 0.80 | S1PR1 (0.52) | S1PR1NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2225375 | 0.79 | S1PR1 (0.44) | S1PR1KDM4EAPP | |
| SCHEMBL2224473 | 0.78 | NPC1 (0.40) | S1PR1NPC1ALDH1A1HPGDAPP | |
| SCHEMBL2228881 | 0.78 | ESR1 (0.38) | S1PR1NPC1HDAC6APP | |
| SCHEMBL15310299 | 0.78 | S1PR1 (0.47) | S1PR1HPGD | |
| SCHEMBL15310300 | 0.77 | HPGD (0.41) | S1PR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | claimed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | claimed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | claimed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, CDK2, CCNT2 | S1PR1 1027/4885NPC1 4602/4885GSK3B 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.